Holen Sie sich die Stockscreener-App
811.45
1.08%
-8.86
Handel nachbörslich:
811.45
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
Increased Demand for Vyvgart Boosted Argenx SE (ARGX) in Q4 - Insider Monkey
Analysts May Have Underestimated Argenx SE's (ARGX) 5 year Revenue Growth - Finviz
Wells Fargo analyst sees potential in Argenx SE’s (ARGX) Vyvgart, increases PT to $1,317 - MSN
Goldman Sachs Assumes Penguin Solutions (PENG) Coverage with Buy Rating, $25 PT - Yahoo Finance
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Insider Monkey
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Yahoo Finance
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Yahoo Finance
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)’s 2026 Growth Despite Revenue Headwinds - Yahoo Finance
Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW) - Yahoo Finance
Assessing argenx (ENXTBR:ARGX) Valuation After Recent Share Price Pullback - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Vyvgart Priority Review Puts Argenx Valuation Gap And Pipeline In Focus - Yahoo Finance
Argenx's (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments - Finviz
12 Best Healthcare Stocks to Buy for 2026 - Insider Monkey
Argenx’s (ARGX) Vyvgart Sales Outperform Expectations Across MG and CIDP Treatments - Yahoo Finance
Wells Fargo Analyst Sees Potential in Argenx SE's (ARGX) Vyvgart, Increases PT to $1,317 - Finviz
argenx SE (ARGX): A Bull Case Theory - Finviz
Why Argenx SE (ARGX) Stock Advanced on Commercial Execution - Finviz
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Jefferies Keeps Their Buy Rating on Argenx Se (ARGX) - The Globe and Mail
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Argenx shares rise as FDA reviews Vyvgart for broader use By Investing.com - Investing.com South Africa
Argenx shares rise as FDA reviews Vyvgart for broader use - Investing.com
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG - Sahm
William Blair reiterates Outperform rating on argenx stock - Investing.com
Argenx shares slip as Q4 results come in broadly in line By Investing.com - Investing.com South Africa
Argenx shares slip as Q4 results come in broadly in line - Investing.com
Wells Fargo Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Sahm
argenx SE stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference - Chartmill
Argenx stock holds steady as TD Cowen reiterates Buy rating By Investing.com - Investing.com South Africa
Argenx stock holds steady as TD Cowen reiterates Buy rating - Investing.com
Argenx founder Tim Hauwermeiren to step down as CEO; Karen Massey named successor - Investing.com India
argenx Announces Leadership Transition Marking Next Evolution of Growth - Sahm
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Sahm
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Argenx SE Sponsored ADR (ARGX) Stock Price History & Data - Traders Union
BofA Securities raises argenx stock price target to $1,006 on strong Vyvgart outlook - Investing.com India
Baird downgrades argenx stock rating to Neutral on valuation concerns By Investing.com - Investing.com South Africa
Baird downgrades argenx stock rating to Neutral on valuation concerns - Investing.com
Argenx stock price target raised to $925 from $860 at RBC Capital By Investing.com - Investing.com South Africa
Argenx stock price target raised to $925 from $860 at RBC Capital - Investing.com
Argenx stock rating maintained at Buy by BofA despite TED trial failure - Investing.com South Africa
Jefferies maintains Buy rating on argenx stock despite failed TED trial - Investing.com
argenx stock rating reiterated at Buy by Guggenheim despite TED study halt - Investing.com South Africa
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Sahm
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
argenx stock tumbles after discontinuing thyroid eye disease studies - Investing.com
Argenx, Navan And 3 Stocks To Watch Heading Into Monday - Sahm
Immunovant: "Buy" On Competitive Batoclimab Landscape And IMVT-1402 Advancement (IMVT) - Seeking Alpha
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance By Investing.com - Investing.com South Africa
Stifel raises argenx stock price target to $1,248 on Vyvgart dominance - Investing.com India
Argenx price target raised to $910 from $800 at UBS on Vyvgart growth By Investing.com - Investing.com South Africa
0.93%
1.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):